A Comparison of Study Designs of Inhaled Agents in Non-Cystic Fibrosis Bronchiectasis (NCFB): Key Differences in the Phase 3 RESPIRE Trials of Ciprofloxacin Dry Powder for Inhalation (DPI)

被引：0
|
作者：
Aksamit, Timothy [1 ]
De Soyza, Anthony [1 ]
Operschall, Elisabeth [1 ]
Bandel, Tiemo-Joerg [1 ]
Wilson, Robert [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
CHEST | 2015年 / 148卷 / 04期
关键词：
D O I：
10.1378/chest.2277297
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
662A
引用
收藏
页数：2
相关论文
共 39 条
  • [31] Efficacy of ciprotioxacin against resistant mucoid or nonmucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokineties after ciprofloxacin DPI treatment
    Obertegger, Sabine
    Weskott, Gabriele
    Surdakowski, Petra
    Glenschek-Sieberth, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [32] Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
    Haworth, Charles S.
    Bilton, Diana
    Chalmers, James D.
    Davis, Angela M.
    Froehlich, Juergen
    Gonda, Igor
    Thompson, Bruce
    Wanner, Adam
    O'Donnell, Anne E.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (03): : 213 - 226
  • [33] Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB)
    O'Donnell, Anne
    Gonda, Igor
    Cipolla, David
    Froehlich, Juergen
    Davis, Angela
    Haworth, Charles
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [34] Tolerability and Pharmacokinetic Properties of Ciprofloxacin Dry Powder for Inhalation in Patients With Cystic Fibrosis: A Phase I, Randomized, Dose-Escalation Study
    Stass, Heino
    Weimann, Boris
    Nagelschmitz, Johannes
    Rolinck-Werninghaus, Claudia
    Staab, Doris
    CLINICAL THERAPEUTICS, 2013, 35 (10) : 1571 - 1581
  • [35] Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study
    Stass, Heino
    Delesen, Heinz
    Nagelschmitz, Johannes
    Staab, Doris
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2015, 28 (02) : 106 - 115
  • [36] Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials (vol 7, pg 213, 2019)
    Haworth, C. S.
    Bilton, D.
    Chalmers, J. D.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (03): : E12 - E12
  • [37] Inhaled Ciprofloxacin (ARD-3150) in Patients with Non-Cystic Fibrosis Bronchiectasis and Frequent Pulmonary Exacerbations: A Pooled Analysis from ORBIT-3 and ORBIT-4
    Chalmers, J. D.
    Davis, A. M.
    Tino, G.
    Gonda, I.
    Froehlich, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [38] Inhaled Liposomal Ciprofloxacin Significantly Reduces Sputum Pseudomonas AerugINOSa (PA) Density And Increases Time To First Exacerbation In A 168 Day Placebo Controlled Study In Non-Cystic Fibrosis Bronchiectasis (Non-CF BE)
    Serisier, D.
    Kolbe, J.
    Greville, H.
    Gonda, I.
    Bruinenberg, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [39] Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials
    Barker, Alan F.
    O'Donnell, Anne E.
    Flume, Patrick
    Thompson, Philip J.
    Ruzi, Jonathan D.
    de Gracia, Javier
    Boersma, Wim G.
    De Soyza, Anthony
    Shao, Lixin
    Zhang, Jenny
    Haas, Laura
    Lewis, Sandra A.
    Leitzinger, Sheila
    Montgomery, A. Bruce
    McKevitt, Matthew T.
    Gossage, David
    Quittner, Alexandra L.
    O'Riordan, Thomas G.
    LANCET RESPIRATORY MEDICINE, 2014, 2 (09): : 738 - 749
1234